TCR2 Tx Appoints Peter Olagunju as Chief Technical Officer
On Tuesday, July 20, TCR2 Therapeutics announced (press release) the appointment of Peter Olagunju as their first Chief Technical Officer (CTO). Below, Celltelligence provides insights on how Peter Olagunju’s extensive cell therapy development and manufacturing experience could accelerate the development and commercialization of TCR2 Tx’s lead asset, gavo-cel (mesothelin targeted TRuC-T) in solid tumors.